SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 94.89 |
| Enterprise Value ($M) | -36.94 |
| Book Value ($M) | 121.55 |
| Book Value / Share | 2.40 |
| Price / Book | 0.78 |
| NCAV ($M) | 91.01 |
| NCAV / Share | 1.79 |
| Price / NCAV | 1.04 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.84 |
| Return on Assets (ROA) | -0.53 |
| Return on Equity (ROE) | -0.57 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.96 |
| Current Ratio | 3.96 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 134.60 |
| Assets | 165.14 |
| Liabilities | 43.59 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -125.14 |
| Net Income | -115.86 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -88.22 |
| Cash from Investing | 47.29 |
| Cash from Financing | 11.68 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 7.00 | -22.95 | |
| 13G/A | Alger Associates Inc | 2.70 | -67.81 | |
| 13G/A | Jennison Associates Llc | 5.10 | -51.41 | |
| 13G/A | Prudential Financial Inc | 5.70 | -50.51 | |
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 3.30 | -37.96 | |
| 13G | T. Rowe Price Investment Management, Inc. | 7.50 | ||
| 13G/A | Adage Capital Management, L.P. | 7.43 | ||
| 13G/A | Vanguard Group Inc | 5.22 | 0.00 | |
| 13G/A | State Street Corp | 1.80 | -65.46 | |
| 13G | Bain Capital Life Sciences Opportunities III, LP | 5.70 | 38.04 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 320,807 | 904,793 | 35.46 | |
| 172,146 | 541,049 | 31.82 | |
| 363,350 | 1,070,655 | 33.94 | |
| 239,615 | 996,816 | 24.04 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BMEA – Biomea Fusion, Inc. | BMRN – BioMarin Pharmaceutical Inc. |
| BPMC – Blueprint Medicines Corporation | CCCC – C4 Therapeutics, Inc. |
| CGC – Canopy Growth Corporation |
Financial data and stock pages provided by
Fintel.io